Qiagen secures EUA for COVID-19 test

By LabPulse.com staff writers

March 29, 2021 -- Qiagen has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for NeuMoDx, a test that helps clinicians distinguish types of respiratory disease.

NeuMoDx Flu A-B/ respiratory syncytial virus (RSV)/SARS-CoV-2 Vantage is a polymerase chain reaction (PCR) assay that will enable clinicians to identify the cause of respiratory viral infection, whether it's due to SARS-CoV-2, influenza, or RSV.

The test has been in use in the European Union since last November, Qiagen said.

Qiagen launches automated sample processing for molecular testing
Qiagen has announced the launch of a fully automated sample processing platform for IVD applications in molecular diagnostic laboratories.
Qiagen, Inovio to partner on cervical dysplasia test
Qiagen and Inovio have announced they will develop a next-generation sequencing test for HPV-linked advanced cervical dysplasia that can be used on Illumina's...
Qiagen plans FDA resubmission of coronavirus rapid antigen test
Qiagen is planning a first-quarter resubmission of its QIAreach rapid antigen test to the U.S. Food and Drug Administration (FDA). In separate news, the...
Qiagen debuts solution for SARS-CoV-2 T-cell research
Qiagen has launched the QuantiFeron SARS-CoV-2 Research Use Only solution to detect T-cell responses to the novel coronavirus. The solution could aid...
Qiagen releases portable SARS-CoV-2 antigen test
Qiagen has launched a portable, digital SARS-CoV-2 antigen test that can analyze more than 30 swab samples per hour. The company developed the QIAreach...

Copyright © 2021 LabPulse.com

Last Updated ls 3/29/2021 12:06:47 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current